Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Étude de phase III, contrôlée, randomisée, de supériorité de galcanézumab versus placebo, chez les patients atteints de migraine difficile à traiter : résultats de l’étude CONQUER
Headaches during pregnancy
Revue Neurologique (Paris). 2020 Aug 21;S0035-3787(20)30622-6. doi: 10.1016/j.neurol.2020.05.012. Online ahead of print. Headaches during pregnancy S de Gaalon 1 , A Donnet 2 PMID: 32838992 DOI: 10.1016/j.neurol.2020.05.012 Abstract Headache during pregnancy is frequent and challenging. A secondary headache is diagnosed in
Migraine and Two-Pore-Domain Potassium Channels
The Neuroscientist. 2020 Jul 27;1073858420940949. doi: 10.1177/1073858420940949. Online ahead of print. Migraine and Two-Pore-Domain Potassium Channels Clément Verkest 1 2 3 , Stephanie Häfner 1 2 , Pablo Ávalos Prado 1 2 , Anne Baron 2 3 , Guillaume
Two-pore-domain potassium channels and molecular mechanisms underlying migraine
Biologie Aujourd’hui 2019;213(1-2):51-57. doi: 10.1051/jbio/2019020. Epub 2019 Jul 5. [Two-pore-domain potassium channels and molecular mechanisms underlying migraine] Perrine Royal 1 , Pablo Ávalos Prado 1 , Brigitte Wdziekonski 1 , Guillaume Sandoz 1 PMID: 31274103 DOI: 10.1051/jbio/2019020 Abstract Migraine is a common, disabling
Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK.
Neuron. 2019 Jan 16;101(2):232-245.e6. doi: 10.1016/j.neuron.2018.11.039. Epub 2018 Dec 17. Royal P1, Andres-Bilbe A2, Ávalos Prado P1, Verkest C3, Wdziekonski B1, Schaub S4, Baron A5, Lesage F3, Gasull X2, Levitz J6, Sandoz G7. Abstract It is often unclear why some
Effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.
Br J Pharmacol. 2018 Nov;175(21):4154-4166. doi: 10.1111/bph.14462. Epub 2018 Sep 22. Verkest C1,2,3, Piquet E3,4, Diochot S1,2,3, Dauvois M1, Lanteri-Minet M3,4,5, Lingueglia E1,2,3, Baron A1,2,3. Abstract BACKGROUND AND PURPOSE: Acid-sensing ion channels (ASICs) are neuronal proton sensors emerging as potential
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22. Reuter U1, Goadsby PJ2, Lanteri-Minet M3, Wen S4, Hours-Zesiger P5, Ferrari MD6, Klatt J5. Abstract BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate,